Immunome, Inc. IMNM 深 沪
等待开盘 04-02 09:30:00 美东时间
22.45
+0.580
+2.65%
华盛通- 最 高23.14
- 今 开22.22
- 成交量 114.82万股
- 最 低 22.22
- 昨 收 21.87
- 总市值 25.40亿
- 52周最高 27.65
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 6.96
- 委 比 -92.86%
- 总股本 1.13亿
- 历史最高 63.78
- 量 比 0.62
- 振 幅 4.21%
- 历史最低 2.09
- 每 手 1
- 风险率 5.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunome Director Philip Wagenheim Disposes of Common Shares Worth USD 1,335,000
Immunome Director Philip Wagenheim Disposes of Common Shares Worth USD 1,335,000 Immunome director Philip Wagenheim reported sales of 36,800 common shares on March 20, 2026. On March 23, 2026, he reported selling 28,200 common shares. After the reported transactions, Philip Wagenheim beneficially ow
03-24 09:24
Immunome Director Jean Jacques Bienaime Acquires Common Shares
Immunome Director Jean Jacques Bienaime Acquires Common Shares Jean Jacques Bienaime, a director, reported an acquisition of common shares of Immunome Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative a
03-12 18:10
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Stephens & Co. Maintains Overweight on Immunome, Lowers Price Target to $30
Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.
03-04 22:02
Immunome: Q4 Earnings Insights
Immunome (NASDAQ:IMNM) reported its Q4 earnings results on Tuesday, March 3, 20...
03-04 05:46
Immunome Q4 EPS $(0.75) Misses $(0.58) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.58) by 29.09 percent. This is a 41.41 percent increase over losses of $(1.28) per share from the
03-04 05:23
UPDATE 3-Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
UPDATE 3-Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion Adds CEO quote in paragraphs 9, 10 and background throughout Feb 23 (Reuters) - Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company sa
02-23 20:47
美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
华尔街顶级机构最新评级：Shopify获上调，Coinbase获下调
这里汇总了华尔街关注度最高、影响市场走势的研报评级。以下是今日投资者需重点关注的评级变动，由 The Fly 整理。 五大上调评级 Shopify （...
02-12 23:25
HC Wainwright & Co. Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $40
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $40.
02-12 19:58
